Shield is working, but cash burn still matters
- Shield, its blood test for colorectal cancer screening, drove the latest beat with about 44,000 tests in Q1 2026.
- Screening revenue rose to $41.6 million in Q1 2026 from $5.7 million a year earlier.
- The core Oncology segment is still the main business, with $205.0 million of Q1 2026 revenue and 36% year-over-year growth.
- Management raised 2026 Screening revenue guidance to $186 million to $198 million.
- The hard part is still turning growth into cash flow while funding the Shield launch.
- A DOJ False Claims Act investigation tied to Guardant360 billing remains a real legal overhang.
Shield has real pull
Guardant Health looks stronger after Q1 2026. Shield, its FDA-approved blood test for colorectal cancer screening, produced about 44,000 tests and $42 million of revenue in the quarter. That was far above the year-ago level of about 9,000 tests and $6 million of revenue.
The raise matters. Management now expects 2026 Screening revenue of $186 million to $198 million, driven by about 230,000 to 245,000 Shield tests. That says doctors and patients are trying the product faster than expected, and early signs from the Quest Diagnostics co-promotion deal look positive.
The older Oncology business also improved. It generated $205.0 million in Q1 2026 revenue, up 36% year over year, on about 86,000 tests. That gives the company a stronger base while it spends heavily to build the screening market.
The bear case did not go away. Guardant is still burning cash because Shield needs sales reps, advertising, payer work, and lab scale. Management says it remains on track for company-wide cash flow breakeven by the end of 2027, but the market already gives the company little room for sloppy execution.
Blood tests, paid per result
Guardant sells liquid biopsy tests. A liquid biopsy is a blood test that looks for cancer signals, such as tumor DNA, without needing a tissue sample. Doctors use these tests to pick cancer drugs, monitor for recurrence, or screen people before symptoms appear.
The company earns money from clinical customers and from drug companies. Clinicians order tests like Guardant360, Reveal, and Shield for patients. Biopharma customers buy testing and data services for research, drug trials, and therapy development.
The model works best when test volume rises, insurers pay at attractive rates, and lab costs fall as more samples run through the system. It breaks if adoption slows, private insurers pay less than expected, or the company has to keep spending at a high level for too long.
Shield changes the scale of the company. Advanced cancer testing is a strong business, but colorectal cancer screening is a much larger market. That is why the launch can create major growth and also why it creates major cash burn.
Cancer tests across stages
Guardant360
Guardant360 helps doctors choose treatments for advanced-stage cancer patients by reading cancer-related genetic changes from blood. It is the key product inside the Oncology base business.
Reveal
Reveal is a minimal residual disease test, which means it looks for tiny signs that cancer may remain after treatment. Its value depends on wider use in recurrence monitoring.
Shield
Shield is the FDA-approved blood test for colorectal cancer screening in average-risk adults. It is the main reason the growth story has improved.
Shield MCD
Shield MCD adds an optional multi-cancer detection results report as part of a data collection effort. It is an early step toward screening beyond colorectal cancer.
Biopharma and Data
This business sells tests and data services to drug companies for research and clinical trials. It grew 17% year over year to $53.0 million in Q1 2026.
MetaSight Diagnostics technology
Guardant acquired MetaSight Diagnostics in Q4 2025 for technology that may improve the broader test portfolio. The payoff is still a pipeline question, not a current revenue driver.
Q1 mix still starts with Oncology
Segment shares use Q1 2026 revenue: Oncology at $205.0 million, Biopharma and Data at $53.0 million, and Screening at $41.6 million. Screening is still the smallest segment by revenue, but it is growing the fastest.
What could break the story
Shield adoption stalls
High impact · Medium oddsThe stock now depends heavily on Shield becoming a common screening choice. Q1 2026 was strong, but the company still has to move from early uptake to repeat, broad use across doctors, patients, and payers. If volume misses the 2026 guide of about 230,000 to 245,000 Shield tests, the growth thesis weakens fast.
Reimbursement pressure
High impact · Medium oddsGuardant needs Medicare and private insurers to pay enough for Shield and its oncology tests. A bad payor mix, slower private coverage, or lower average selling prices would hurt gross margin. That would make it harder to fund the launch without raising more capital.
Cash burn lasts too long
High impact · Medium oddsThe company is investing heavily in sales and marketing for Shield. Management says it remains committed to company-wide cash flow breakeven by the end of 2027. If spending stays high while revenue growth slows, the path to self-funding gets pushed out.
DOJ billing investigation
High impact · Low oddsGuardant disclosed a civil investigative demand from the U.S. Attorney for the Northern District of California under the False Claims Act. The request relates to billing government-funded programs for Guardant360. The company says it is cooperating, but an unfavorable outcome could bring penalties or operating changes.
Pipeline timing slips
Medium impact · Medium oddsFuture growth assumes better versions of key tests, including Shield V2 and Reveal Ultra. Management has sounded less rushed on Shield V2 timing, which creates a risk that competitors narrow the gap. The current first-mover lead helps, but it does not remove the need to keep improving test performance.
Guidelines take longer
Medium impact · Medium oddsAmerican Cancer Society guideline inclusion for blood-based colorectal cancer screening could help private payor adoption. Management has said an update should come soon, but it has been delayed. If guidelines do not move, some payors and doctors may wait.
In one breath
What does Guardant Health do?
Guardant Health makes blood tests for cancer. Its tests help doctors choose treatments, watch for recurrence after therapy, and screen average-risk adults for colorectal cancer.
Why is Shield important for GH stock?
Shield opens a much larger screening market than Guardant's older advanced cancer testing business. In Q1 2026, Shield produced about 44,000 tests and $42 million of revenue, which pushed management to raise full-year Screening guidance.
Is Guardant Health profitable?
The company as a whole is still not cash flow breakeven because it is spending heavily on Shield. Management says the core business excluding screening is improving and that company-wide cash flow breakeven is targeted by the end of 2027.
What is the biggest legal risk for Guardant?
The main legal overhang is a DOJ False Claims Act investigation tied to Guardant360 billing for government-funded programs. The company says it is cooperating, but the timing and financial impact are still open questions.